The IGF-Axis and Diabetic Retinopathy Before and After Gastric Bypass Surgery

Obesity Surgery

Volumn 27, Issue 2, 2017, Pages 408-415

  Brynskov, Troels ^a,b   Laugesen, Caroline Schmidt ^a   Floyd, Andrea Karen ^a   Frystyk, Jan ^c,d   Sørensen, Torben Lykke ^a,b  

^a ZEALAND UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bariatric surgery; Bioactive IGF; Diabetes; Diabetic retinopathy; Gastric bypass surgery; IGF I; IGF II; IGFBP 1; IGFBP 3

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRIACYLGLYCEROL; BIOLOGICAL MARKER; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DIABETIC RETINOPATHY; EYE EXAMINATION; FEMALE; FOLLOW UP; GASTRIC BYPASS SURGERY; GLUCOSE METABOLISM; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; HUMAN CELL; LAPAROSCOPIC SURGERY; LIPID METABOLISM; MALE; MICROANEURYSM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; COMPLICATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; REHABILITATION; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADULT; BIOMARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; GASTRIC BYPASS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SIGNAL TRANSDUCTION; SOMATOMEDINS; TREATMENT OUTCOME;

EID: 84979976487     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-016-2303-0     Document Type: Article

References (46)

1. The Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the diabetes control and complications trial. Arch Ophthalmol. 1998;116:874–86.
2. Henricsson M, Berntorp K, Fernlund P, et al. Progression of retinopathy in insulin-treated type 2 diabetic patients. Diabetes Care. 2002;25:381–5.
3. Poulaki V, Joussen AM, Mitsiades N, et al. Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. AJPA. 2004;165:457–69.
4. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366:1227–39.
5. Frystyk J. The growth hormone hypothesis - 2005 revision. Horm Metab Res. 2005;37(Suppl 1):44–8.
6. Chen J-W, Ledet T, Orskov H, et al. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab. 2003;284:E1149–55.
7. Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov. 2007;6:821–33.
8. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med. 2014;370:2002–13.
9. Madsbad S, Dirksen C, Holst JJ. Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol. 2014;2:152–64.
10. Brynskov T, Laugesen CS, Lykke Svenningsen A, et al. Perioperative monitoring of diabetic retinopathy in patients with type 2 diabetes undergoing gastric bypass surgery: a prospective observational study. Obes Surg. 2016;26:1279–86.
11. Savastano S, Di Somma C, Barrea L, et al. The complex relationship between obesity and the somatropic axis: the long and winding road. Growth Hormon IGF Res. 2014;24:221–6.
12. Kotronen A, Lewitt M, Hall K, et al. Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. J Clin Endocrinol Metab. 2008;93:4867–72.
13. Reinhard M, Frystyk J, Jespersen B, et al. Effect of hyperinsulinemia during hemodialysis on the insulin-like growth factor system and inflammatory biomarkers: a randomized open-label crossover study. BMC Nephrol. 2013;14:80.
14. Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014;99:1712–21.
15. Friedrich N, Wolthers OD, Arafat AM, et al. Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays. J Clin Endocrinol Metab. 2014;99:1675–86.
16. The Circulating IGF System in Hepatocellular Carcinoma. The Impact of Liver Status and Treatment. Growth Horm. IGF Res. 2015;25:174–81.
17. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21:2191–2.
18. Klein R, Klein BE, Magli YL, et al. An alternative method of grading diabetic retinopathy. Ophthalmology. 1986;93:1183–7.
19. Klein R, Klein BE, Moss SE. How many steps of progression of diabetic retinopathy are meaningful? The Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol. 2001;119:547–53.
20. Merimee TJ, Zapf J, Froesch ER. Insulin-like growth factors. Studies in diabetics with and without retinopathy. N Engl J Med. 1983;309:527–30.
21. Janssen JA, Jacobs ML, Derkx FH, et al. Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82:2809–15.
22. Feldmann B, Jehle PM, Mohan S, et al. Diabetic retinopathy is associated with decreased serum levels of free IGF-I and changes of IGF-binding proteins. Growth Hormon IGF Res. 2000;10:53–9.
23. Dills DG, Moss SE, Klein R, et al. Is insulinlike growth factor I associated with diabetic retinopathy? Diabetes. 1990;39:191–5.
24. Hyer SL, Sharp PS, Sleightholm M, et al. Progression of diabetic retinopathy and changes in serum insulin-like growth factor I (IGF I) during continuous subcutaneous insulin infusion (CSII). Horm Metab Res. 1989;21:18–22.
25. Frystyk J, Bek T, Flyvbjerg A, et al. The relationship between the circulating IGF system and the presence of retinopathy in type 1 diabetic patients. Diabet Med. 2003;20:269–76.
26. Brugts MP, Ranke MB, Hofland LJ, et al. Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays. J Clin Endocrinol Metab. 2008;93:2539–45.
27. Leung K-C, Johannsson G, Leong GM, et al. Estrogen regulation of growth hormone action. Endocr Rev. 2004;25:693–721.
28. Vestergaard PF, Hansen M, Frystyk J, et al. Serum levels of bioactive IGF1 and physiological markers of ageing in healthy adults. Eur J Endocrinol. 2014;170:229–36.
29. Grant MB, Mames RN, Fitzgerald C, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care. 2000;23:504–9.
30. Kirkegaard C, Nørgaard K, Snorgaard O, et al. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in type I (insulin-dependent) diabetes mellitus. Acta Endocrinol. 1990;122:766–72.
31. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group. The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology. 2001;108:2266–72.
32. Sandhu MS, Heald AH, Gibson JM. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet. 2002;359:1740–5.
33. Rajpathak SN, He M, Sun Q, et al. Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabetes. 2012;61:2248–54.
34. Heald AH, Cruickshank JK, Riste LK, et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia. 2001;44:333–9.
35. Frystyk J, Vestbo E, Skjaerbaek C. Free insulin-like growth factors in human obesity. Metab Clin Exp. 1995;44:37–44.
36. Frystyk J, Brick DJ, Gerweck AV, et al. Bioactive insulin-like growth factor-I in obesity. J Clin Endocrinol Metab. 2009;94:3093–7.
37. Frystyk J, Skjaerbaek C, Vestbo E, et al. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev. 1999;15:314–22.
38. Pellitero S, Granada ML, Martínez E, et al. IGF1 modifications after bariatric surgery in morbidly obese patients: potential implications of nutritional status according to specific surgical technique. Eur J Endocrinol. 2013;169:695–703.
39. Giusti V, Gasteyger C, Suter M, et al. Gastric banding induces negative bone remodelling in the absence of secondary hyperparathyroidism: potential role of serum C telopeptides for follow-up. Int J Obes Relat Metab Disord. 2005;29:1429–35.
40. Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev. 2009;30:417–37.
41. Wheatcroft SB, Kearney MT. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and −2: implications for metabolic homeostasis. Trends Endocrinol Metab. 2009;20:153–62.
42. Rubino F, Gagner M, Gentileschi P, et al. The early effect of the roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240:236–42.
43. Pardina E, Ferrer R, Baena-Fustegueras JA, et al. The relationships between IGF-1 and CRP, NO, leptin, and adiponectin during weight loss in the morbidly obese. Obes Surg. 2010;20:623–32.
44. Edén Engström B, Burman P, Holdstock C, et al. Effects of gastric bypass on the GH/IGF-I axis in severe obesity--and a comparison with GH deficiency. Eur J Endocrinol. 2006;154:53–9.
45. Itariu BK, Zeyda M, Prager G, et al. Insulin-like growth factor 1 predicts post-load hypoglycemia following bariatric surgery: a prospective cohort study. PLoS One. 2014;9:e94613–9.
46. Vilarrasa N, Gómez JM, Elio I, et al. Evaluation of bone disease in morbidly obese women after gastric bypass and risk factors implicated in bone loss. Obes Surg. 2009;19:860–6.